Sage Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Sage Therapeutics has a total shareholder equity of $551.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $622.4M and $70.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$569.15m |
| Equity | US$551.84m |
| Total liabilities | US$70.60m |
| Total assets | US$622.43m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: SG7's short term assets ($605.0M) exceed its short term liabilities ($60.4M).
Long Term Liabilities: SG7's short term assets ($605.0M) exceed its long term liabilities ($10.2M).
Debt to Equity History and Analysis
Debt Level: SG7 is debt free.
Reducing Debt: SG7 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SG7 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if SG7 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.